The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal

Abstract Background Erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, was approved for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg. We reviewed the available literature to understand if patie...

Full description

Bibliographic Details
Published in:	The Journal of Headache and Pain
Main Authors:	Raffaele Ornello, Cindy Tiseo, Ilaria Frattale, Giulia Perrotta, Carmine Marini, Francesca Pistoia, Simona Sacco
Format:	Article
Language:	English
Published:	BMC 2019-10-01
Subjects:	Migraine Calcitonin gene-related peptide Migraine prevention Monoclonal antibodies Erenumab
Online Access:	http://link.springer.com/article/10.1186/s10194-019-1054-4

Similar Items

Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
by: Raffaele Ornello, et al.
Published: (2020-08-01)

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
by: Raffaele Ornello, et al.
Published: (2020-04-01)

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
by: Raffaele Ornello, et al.
Published: (2021-03-01)

Real-world effectiveness of erenumab in Japanese patients with migraine
by: Keisuke Suzuki, et al.
Published: (2024-02-01)

Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
by: Michael Lowe, et al.
Published: (2022-07-01)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
by: De Matteis E, et al.
Published: (2022-04-01)

Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention
by: Shuchita Garg, et al.
Published: (2020-01-01)

A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study
by: Shengyuan Yu, et al.
Published: (2022-11-01)

Assessment and characteristics of Erenumab therapy on migraine management
by: Haitham Saeed, et al.
Published: (2022-08-01)

Efficacy and Tolerability of Erenumab and Topiramate for Prevention of Chronic Migraine: A Retrospective Cohort Study
by: Eslam El Nebrisi, et al.
Published: (2024-10-01)

The course of headache after the end of treatment with erenumab in patients with episodic and chronic migraine
by: Anna A. Garmanova, et al.
Published: (2024-05-01)

Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study
by: Charly Gaul, et al.
Published: (2024-10-01)

Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany
by: Ja Bin Hong, et al.
Published: (2023-10-01)

Erenumab efficacy predictors for chronic migraine
by: Nina V. Vashchenko
Published: (2022-02-01)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
by: Agaath Hedina Manickam, et al.
Published: (2021-08-01)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
by: Shigekazu Kitamura, et al.
Published: (2023-09-01)

MicroRNA profiling in women with migraine: effects of CGRP-targeting treatment
by: Raffaele Ornello, et al.
Published: (2024-05-01)

Erenumab effectiveness and safety: comparison of real-life data and clinical trial results
by: Austėja Dapkutė, et al.
Published: (2021-12-01)

One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study
by: M. Lanteri-Minet, et al.
Published: (2023-11-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01)

Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?
by: Michele Torrisi, et al.
Published: (2023-05-01)

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis
by: Patricia Pozo-Rosich, et al.
Published: (2024-03-01)

Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON)
by: Hartmut Göbel, et al.
Published: (2024-09-01)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
by: Todd Schwedt, et al.
Published: (2018-10-01)

Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study
by: Marc Ehrlich, et al.
Published: (2022-11-01)

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
by: Stewart J Tepper, et al.
Published: (2021-07-01)

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
by: Bianca Raffaelli, et al.
Published: (2020-05-01)

A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
by: Giuseppe Tringali, et al.
Published: (2020-10-01)

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
by: Ronan Mahon, et al.
Published: (2024-03-01)

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
by: Anna V. Berdnikova, et al.
Published: (2023-10-01)

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
by: Lucas Hendrik Overeem, et al.
Published: (2023-03-01)

Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial
by: Koichi Hirata, et al.
Published: (2021-09-01)

Sequential use of OnabotulinumtoxinA and Erenumab in Chronic Migraine: Retrospective Real-World Report on Bidirectional Switching
by: Carolin Luisa Hoehne, et al.
Published: (2025-08-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
by: Magdalena Nowaczewska, et al.
Published: (2022-05-01)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
by: Hugo Sevivas, et al.
Published: (2022-06-01)

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
by: Simona Sacco, et al.
Published: (2022-06-01)

Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data
by: David Chandler, et al.
Published: (2021-09-01)

Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis
by: Robert Urman, et al.
Published: (2024-08-01)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
by: Edoardo Caronna, et al.
Published: (2021-10-01)

Lichenoid drug eruption induced by erenumab
by: Meryl Musicante, BS, et al.
Published: (2023-02-01)